Clinical trial
A Single-Arm, Exploratory Study of 4 Additional Cycles of Trastuzumab Rezetecan (T-DXh) as Neoadjuvant Therapy in Patients With Early or Locally Advanced HER2-Positive Breast Cancer Who Have Non-pCR After TCbHP Neoadjuvant Therapy
NCT07589699 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Arm, Exploratory Study of 4 Additional Cycles of Trastuzumab Rezetecan (T-DXh) as Neoadjuvant Therapy in Patients With Early or Locally Advanced HER2-Positive Breast Cancer Who Have Non-pCR After TCbHP Neoadjuvant Therapy
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- May 31, 2026
- Completion date
- December 31, 2031
- Enrollment
- 59 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, early-stage breast cancer, her2-positive breast cancer, locally advanced breast cancer